Follow the Evommune, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €454.9m. The latest transaction was disclosed on 10 July 2026 (Acquisition). Among the most active insiders: Carver Kyle. All data is accessible without an account.
34
Insider Decl.
n/a
Thresholds
€142,626
3 ops.
Buy Volume
€636,992
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Evommune, Inc. Buy (bullish), based on 7 analysts. Average price target: US$31.14.
41Σ signal
Buys €142,626€636,992 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Evommune, Inc. is a company listed on the XNAS market, specializing in the development of innovative solutions for the healthcare sector. It focuses on research and commercialization of treatments for autoimmune diseases.